Related Experiment Video
Updated: Jul 29, 2025

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
Subclinical Vascular Composites Predict Clinical Cardiovascular Disease, Stroke, and Dementia: The Multi-Ethnic Study
Insights
Subclinical cardiovascular disease (CVD) measures, specifically arteriosclerosis and atherosclerosis, can predict future heart disease, stroke, and dementia events. These vascular markers offer valuable insights beyond traditional risk scores.
Area of Science:
- Cardiovascular Medicine
- Neuroscience
- Epidemiology
Background:
- Subclinical cardiovascular disease (CVD) indicators may reveal biological mechanisms underlying increased risk for coronary heart disease (CHD) events, stroke, and dementia.
- These risks may exceed predictions from conventional risk assessment tools.
Conclusions:
- Subclinical vascular composites, particularly those reflecting arteriosclerosis and atherosclerosis, show promise as biomarkers.
- These biomarkers can elucidate vascular pathways contributing to major adverse cardiovascular and neurological events.
- The findings suggest these composites may enhance risk prediction for cardiovascular disease, stroke, and dementia.
Background:
Subclinical cardiovascular disease (CVD) measures may reflect biological pathways that contribute to increased risk for coronary heart disease (CHD) events, stroke, and dementia beyond conventional risk scores.
Methods:
The Multi-Ethnic Study of Atherosclerosis (MESA) followed 6,814 participants (45-84 years of age) from baseline in 2000-2002 to 2018 over 6 clinical examinations and annual follow-up interviews. MESA baseline subclinical CVD procedures included: seated and supine blood pressure, coronary calcium scan, radial artery tonometry, and carotid ultrasound. Baseline subclinical CVD measures were transformed into z-scores before factor analysis to derive composite factor scores. Time to clinical event for all CVD, CHD, stroke and ICD code-based dementia events were modeled using Cox proportional hazards models reported as area under the curve (AUC) with 95% Confidence Intervals (95%CI) at 10 and 15 years of follow-up. All models included all factor scores together and adjustment for conventional risk scores for global CVD, stroke, and dementia.
Results:
After factor selection, 24 subclinical measures aggregated into four distinct factors representing: blood pressure, arteriosclerosis, atherosclerosis, and cardiac factors. Each factor significantly predicted time to CVD events and dementia at 10 and 15 years independent of each other and conventional risk scores. Subclinical vascular composites of arteriosclerosis and atherosclerosis best predicted time to clinical events of CVD, CHD, stroke, and dementia. These results were consistent across sex and racial and ethnic groups.
Conclusions:
Subclinical vascular composites of arteriosclerosis and atherosclerosis may be useful biomarkers to inform the vascular pathways contributing to events of CVD, CHD, stroke, and dementia.
More Related Videos
09:43Multimodal Study of Murine Cardiovascular Remodeling: Four-Dimensional Ultrasound and Mass Spectrometry Imaging
Published on: January 10, 2025
10:11Fundus Photography as a Convenient Tool to Study Microvascular Responses to Cardiovascular Disease Risk Factors in Epidemiological Studies
Published on: October 22, 2014
Related Concept Videos
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Coronary Artery Disease I: Introduction
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Coronary Artery Disease III: Clinical Manifestations
Atherosclerosis III: Management